1. Home
  2. FNWD vs ADCT Comparison

FNWD vs ADCT Comparison

Compare FNWD & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$43.26

Market Cap

147.7M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.16

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
ADCT
Founded
1994
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.7M
136.1M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
FNWD
ADCT
Price
$43.26
$1.16
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$37.50
$7.75
AVG Volume (30 Days)
10.5K
1.5M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
1.51%
N/A
EPS Growth
N/A
30.86
EPS
1.00
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
$66.49
P/E Ratio
$43.03
N/A
Revenue Growth
N/A
14.85
52 Week Low
$30.05
$0.78
52 Week High
$45.90
$4.98

Technical Indicators

Market Signals
Indicator
FNWD
ADCT
Relative Strength Index (RSI) 54.11 48.95
Support Level $36.08 $1.03
Resistance Level $45.90 $1.20
Average True Range (ATR) 0.56 0.08
MACD -0.46 0.02
Stochastic Oscillator 14.95 57.00

Price Performance

Historical Comparison
FNWD
ADCT

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: